We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Discovery
- Leishmania spp.
- Life cycle
- An important Neglected Tropical Disease (NTD)
- Public health importance of cutaneous leishmaniasis
- Worldwide distribution of leishmaniasis
- Leishmania species
- Risk factors: poverty
- Risk factors: conflict
- Old world CL outbreaks linked to war
- War and displacement (Syria and conflict area)
- Cutaneous leishmaniasis in travellers and soldiers
- Clinical aspects
- Different presentations of cutaneous leishmaniasis
- Cutaneous lesions due to L. major
- Diffuse cutaneous leishmaniasis (DCL)
- Mucocutaneous leishmaniasis (MCL) - Espundia
- Mucocutaneous lesions are associated with presence of a virus in parasites
- Leishmaniasis recidivans (LR)
- CL scarring: social stigma and depression
- What determines development of disease
- Diagnosis of cutaneous leishmaniasis
- Parasitological diagnosis
- Leishmaniasis treatment: main drugs used
- Questions influencing decision to treat
- Challenges of control
- Current methods of control
- Summary
Topics Covered
- Leishmania spp.
- Public health importance of CL
- Risk factors of CL
- Clinical aspects of CL
- L. major lesions
- Diffuse cutaneous leishmaniasis (DCL)
- Mucocutaneous leishmaniasis (MCL)
- Leishmaniasis recidivans (LR)
- Challenges and methods of control
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Chance, M. and Acosta-Serrano, Á. (2025, June 30). Cutaneous leishmaniasis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 1, 2025, from https://doi.org/10.69645/WCNC3884.Export Citation (RIS)
Publication History
- Published on June 30, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
- There are no commercial/financial matters to disclose.
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Michael Chance,
and I would like to
present a talk on
cutaneous leishmaniasis
prepared in collaboration
with a colleague, Professor
Alvaro Acosta-Serrano.
The topic of visceral
leishmaniasis has been
the subject of another
separate talk in the series.
0:17
Descriptions of the
disease we now call
cutaneous leishmaniasis
can be found in
19th century publications,
and were usually
given colloquial names with
a geographical association.
For example, Delhi
boil, Aleppo boil,
Baghdad boil and oriental sore.
At the end of the century,
the etiological agent of these
conditions was discovered.
The first slide shows
the photographs of some
of the investigators
important in the
identification of
the parasite causing
leishmaniasis.
The first description
was made by
David Cunningham in 1885,
who examined sections of
a lesion of a patient
with Delhi boil.
However, he considered
the parasites that he saw
to be the spores produced
by a fungal infection.
Pyotr Borovsky, a
Russian military surgeon
working in Tashkent
provided in 1898,
the first useful
description of the parasite
in the samples of a Sart sore.
This publication, unfortunately,
remained unnoticed for decades.
Our understanding of the
parasite advanced in 1903
when independently,
William Leishman and
Charles Donovan reported
parasites in samples from
patients with visceral
leishmaniasis.
These parasites became known
as Leishman-Donovan or
LD bodies and were subsequently
termed amastigotes.
In the same year, 1903,
Ronald Ross suggested
the binomial name of
Leishmania donovani for
the parasite causing
visceral leishmaniasis
and thus established
the term leishmaniasis for
the disease caused
by these parasites.
In the same year, James Wright,
working in Massachusetts,
examining material from
a cutaneous lesion from
an Armenian girl gave
a very detailed and
accurate description of
the parasites and included
photomicrographs.
It is interesting that most
of the early investigators in
these studies held posts
as army medical staff.
The panel on bottom
left in the slide shows
the appearance of amastigotes of
Leishmania in stained smears.
Amastigotes are small, only
about 2-4 μm in diameter.
Their features can
be seen more clearly
in the slides dealing
with diagnosis.
And if you're interested in
the history of leishmaniasis,
it is dealt with in detail in
the paper by Dietmar Steverding.